Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Hanna Urjasz"'
Autor:
Konrad Lewandowski, Agnieszka Karbownik, Andrzej Czyrski, Hanna Urjasz, Joanna Stanisławiak-Rudowicz, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Acta Poloniae Pharmaceutica, Vol 81, Iss 2, Pp 263-278 (2024)
Olaparib, an oral poly-ADP ribose polymerase (PARP) inhibitor, is a relatively new anticancer drug. It is essential to find TDM-guided dosage for better safety and tolerability of patients. However, first, it is important to develop a suitable analyt
Externí odkaz:
https://doaj.org/article/d88f74306b6e406baae09e6342e10085
Autor:
Edyta Szałek, Arkadiusz Spychala, Patrycja Kozanecka, Hanna Urjasz, Tomasz Grabowski, Anna Wolc, Elżbieta Długosz, Witold Kycler, Edmund Grześkowiak, Agnieszka Karbownik
Publikováno v:
Acta Poloniae Pharmaceutica - Drug Research. 79:401-407
Autor:
Dorota Kołodziej, Danuta Szkutnik-Fiedler, Hanna Urjasz, Tomasz Grabowski, Ryszard Bosacki, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Acta Poloniae Pharmaceutica - Drug Research. 78:755-759
Autor:
Tomasz Grabowski, Anna Wolc, Agnieszka Karbownik, Anna Stachowiak, Katarzyna Sobańska, Edmund Grześkowiak, Hanna Urjasz, Edyta Szałek, Agnieszka Szczecińska, Joanna Stanisławiak-Rudowicz
Publikováno v:
Pharmacological Reports
Background Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepat
Autor:
Monika Balcerkiewicz, Danuta Szkutnik-Fiedler, Tomasz Grabowski, Irina Pilipczuk, Łukasz Wyrowski, Hanna Urjasz, Edmund Grześkowiak, Michał Michalak
Publikováno v:
Pharmacological Reports. 69:555-559
Background The combined use of tramadol with selective serotonin and norepinephrine reuptake inhibitors e.g. venlafaxine may be associated with serotonin syndrome. No previous studies exist examining the influence of a weak CYP2D6 inhibitor venlafaxi
Autor:
Katarzyna Sobańska, Tomasz Grabowski, Anna Stachowiak, Hanna Urjasz, Agnieszka Szczecińska, Agnieszka Karbownik, Edyta Szałek, Anna Wolc, Joanna Stanisławiak-Rudowicz, Edmund Grześkowiak
Publikováno v:
Pharmacological Reports
Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepatocellular c
Autor:
Michał Michalak, Tomasz Grabowski, Hanna Urjasz, Justyna Lisiecka, Danuta Szkutnik-Fiedler, Edmund Grześkowiak, Hanna Billert
Publikováno v:
Pain Medicine. 17:1407-1415
Objective . Systemic inflammation may change the bioavailability and pharmacokinetics of opioids. However, there are insufficient data on morphine pharmacokinetics in mild inflammatory conditions. This study aimed to determine the pharmacokinetics of
Autor:
Edmund Grześkowiak, Emilia Mierzwa, Aleksandra Głęboka, Agnieszka Karbownik, Hanna Urjasz, Edyta Szałek
Publikováno v:
Contemporary Oncology
Aim of the study The subject of study was the stability of cisplatin in concentrate in glass vials and diluted in polyethylene (PE) bags stored at 15–25°C for up to 30 days. Material and methods Original vials of cisplatin injection (1 mg/ml, Teva
Autor:
Agnieszka Kamińska, Monika Balcerkiewicz, Dawid Murawa, Edyta Szałek, Hanna Urjasz, Edmund Grześkowiak
Publikováno v:
Współczesna Onkologia. 3:142-146
of fludarabine phosphate in concentrate in glass containers and diluted with sodium chloride 0.9% in polyethylene (PE) bags. Material and methods: Solutions of fludarabine phosphate 25 mg/ml (concentrate) in glass containers (n = 6) were opened and s
Publikováno v:
Journal of Molecular Structure. 738:271-274